Andere talen Centessa Pharmaceuticals plc

Aandelen

CNTA

US1523091007

Vertraagde tijd Nasdaq Andere beurzen 21:50:05 23-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
9,395 ^USD	-6,05%		-14,82%	+18,03%

22/04	Centessa Pharmaceuticals plc kondigt geopende IND aan voor ORX750	CI
28/03	Centessa Pharmaceuticals plc rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Centessa Pharmaceuticals Announces Open IND for ORX750, Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024	16:08
Centessa Pharmaceutical Gets FDA's Approval to Begin Phase 1 Trial of Narcolepsy Drug Candidate	22/04
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024	22/04
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024	22/04
Centessa Pharmaceuticals plc Announces Open IND for ORX750	22/04
Centessa Pharmaceuticals plc Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Centessa Pharmaceuticals plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/03
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023	28/03
Centessa Pharmaceuticals Insider Sold Shares Worth $607,960, According to a Recent SEC Filing	26/03
Centessa Pharmaceuticals : March Corporate Overview	05/03
Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference	22/02
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)	09/02
Scion Life Sciences Launches with Oversubscribed $310 Million Fund to Create and Build Exceptional Biotech Companies	08/02
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences	22/01
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences	22/01
ADRs End Lower, WISekey International Holding Ltd. Declines 17.3%	17/01
Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference	13/12
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia	11/12
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia	10/12
Centessa Pharmaceuticals plc Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2A Study of Serpinpc for the Treatment of Hemophilia	10/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Centessa Pharmaceuticals plc

Aandelen

CNTA

US1523091007

Andere talen

Filters